

Title (en)
GPE ANALOGS

Title (de)
GPE ANALOGE

Title (fr)
ANALOGUES DE GPE

Publication
EP 1351976 A2 20031015 (EN)

Application
EP 01968959 A 20010824

Priority
• NZ 50653400 A 20000824
• US 0141883 W 20010824

Abstract (en)
[origin: WO216408A2] The invention relates to GPE analogs, particularly GPE analogs capable of inducing an equivalent physiological effect to GPE within a patient. Such GPE analogs include peptides where the Gly of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Pro; where the Pro of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Gly; and where the Glu of Gly-Pro-Glu is replaced by any of Asn, Asp, or Gln. The GPE analogs of the invention have application in any method of therapy or prophylaxis in which GPE has application. These applications include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS. The GPE analogs will normally be administered as part of a pharmaceutical composition or preparation.

IPC 1-7
C07K 5/083; **C07K 5/08**; **A61P 25/00**

IPC 8 full level
A61P 25/00 (2006.01); **C07K 5/083** (2006.01); **C07K 5/093** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)
A61P 25/00 (2017.12); **C07K 5/0806** (2013.01); **C07K 5/0819** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)
See references of WO 0216408A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0216408 A2 20020228; **WO 0216408 A3 20030424**; AU 8916001 A 20020304; EP 1351976 A2 20031015

DOCDB simple family (application)
US 0141883 W 20010824; AU 8916001 A 20010824; EP 01968959 A 20010824